DRD2 and neuroblastoma: Treatment with the D1R agonist SKF 38393 and the D2R agonist quinpirole activates ERK signaling in primary cultured striatal neurons [54], and in cultured neuroblastoma cells, treatment with the D1R agonist SKF 38393 results in oxidative stress and cytotoxicity via ERK activation [55].